HOBOKEN, NJ, May 13 /CNW/ - Anavex Life Sciences Corp. ("Anavex")
(OTCBB: AVXL) today announced the appointment of Robert Chisholm to the
Board of Directors. As a finance and administration executive with more
than 25 years of experience, Mr. Chisholm brings to Anavex significant
expertise in corporate finance, strategic business initiatives and the
unique requirements of growth-oriented public companies.
Mr. Chisholm is currently an officer and partner of Emprise Capital
Corp, a private company focused on advising portfolio companies on
managing finances, including development and implementation of
comprehensive budgeting processes, public market listings and oversight
of contract negotiations.
"We are privileged to welcome a finance executive of Robert's caliber to
our Board. His track record of success coupled with his experience and
insight will contribute significantly to the oversight and operations
of Anavex," said Dr. Cameron Durrant, Executive Chairman of Anavex.
"Anavex is doing important work in the field of Alzheimer's drug
research and development. Unfortunately, today, an increasing number of
people are affected by, or have loved ones, or know someone who has
been affected in some way by this disease. I am looking forward to
working with both the Board and the executive team as we move the
company to the next level," said Mr. Chisholm.
Mr. Chisholm has been the Chief Financial Officer and a director of
Savary Capital Corp. since March 2011, of Windamere Ventures Ltd.
(formerly Advanced Vision Systems Corp.) since May 2010, and of
Brookwater Ventures since December 2009. Mr. Chisholm is also a member
of the Board of Directors for Seymour Ventures.
Mr. Chisholm served as CFO for PNI Digital Media (formerly PhotoChannel
Networks Inc.) between September 2001 and March 2009 and joined PNI's
Board of Directors in April 2009. Prior to 2001, Mr. Chisholm was CFO
for SCS Solars Computing Systems Inc.
In addition, Mr. Chisholm's background includes previous appointments as
CFO and a director of Ocean Park Ventures Corp. and CFO of Tiger
Pacific Mining Corp.
Mr. Chisholm holds a professional accounting designation from the
Certified Management Accountants of Canada and received his BBA with a
major in accounting from Saint Francis Xavier University in Nova
In addition, Anavex announces the departure of David Tousley as CFO. The
company thanks for him for his dedicated service to the company and
wishes him well in his future endeavors. Anavex's President, Harvey
Lalach, will serve as the company's interim CFO.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and
development of novel drug candidates for the treatment of neurological
diseases and cancer. The Anavex proprietary SIGMACEPTOR™ Discovery
Platform involves the rational design of drug compounds targeted to
specific receptors involved in the modulation of multiple cellular
biochemical signaling pathways.
The SIGMACEPTOR™-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer's disease, epilepsy, depression, pain). The company's lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publicly traded company under the symbol "AVXL".
SOURCE Anavex Life Sciences Corp.
For further information:
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092